← ANALYST RATINGS · TIPRANKS
Nurix Therapeutics (NRIX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy1 Hold0 Sell
Ratings of 8 analysts in the last 3 months · top analysts only12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $34.12, the highest $41.00, the lowest $25.00. The average is +39.7% from the last price of $24.42.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $27.00 → $26.00−3.7% | Hold | +6.5% | Upgrade | 17.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $26.00 → $25.00−3.8% | Hold | +2.4% | Reiterated | 17.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 → $27.00−3.6% | Buy | +10.6% | Upgrade | 17.10.26on TipRanks 10:05 | — | |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $34.00 → $36.00+5.9% | Buy | +47.4% | Reiterated | 16.10.26on TipRanks 06:25 | −1.0% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.50 → $26.00+10.6% | Hold | +6.5% | Reiterated | 16.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.50 → $26.00+10.6% | Hold | +6.5% | Upgrade | 16.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.50 → $26.00+10.6% | Hold | +6.5% | Reiterated | 16.10.26on TipRanks 04:05 | — | |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $38.00 | Buy | +55.6% | Reiterated | 15.10.26on TipRanks 08:40 | +5.1%next day −1.0% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $28.00 → $32.00+14.3% | Buy | +31.0% | Reiterated | 13.10.26on TipRanks 07:55 | −0.1%next day +8.0% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $34.00 → $33.00−2.9% | Buy | +35.1% | Reiterated | 13.10.26on TipRanks 07:50 | −0.1%next day +8.0% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $33.00 → $36.00+9.1% | Buy | +47.4% | Reiterated | 13.10.26on TipRanks 07:15 | −0.1%next day +8.0% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $35.00 | Buy | +43.3% | Assigned | 13.10.26on TipRanks 07:05 | −0.1%next day +8.0% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $40.00 → $41.00+2.5% | Buy | +67.9% | Reiterated | 13.10.26on TipRanks 06:40 | −0.1%next day +8.0% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $36.00 → $35.00−2.8% | Buy | +43.3% | Assigned | 12.10.26on TipRanks Oct 13 07:05 | −0.8%next day −0.1% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $25.00 | Hold | +2.4% | Reiterated | 01.09.26on TipRanks 19:10 | −1.3%next day −3.0% · 5 days +0.9% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $34.00 | Buy | +39.2% | Reiterated | 04.08.26on TipRanks 08:32 | +4.5%next day +1.9% · 5 days +5.2% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $23.00 → $31.00+34.8% | Buy | +26.9% | Assigned | 22.07.26on TipRanks 21:03 | +1.8%next day −1.6% · 5 days −1.1% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $45.00 | Buy | +84.3% | Reiterated | 08.07.26on TipRanks 09:35 | −0.1%next day +0.7% · 5 days −3.2% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $30.00 → $32.00+6.7% | Buy | +31.0% | Assigned | 01.07.26on TipRanks 07:53 | −1.3%next day +0.4% · 5 days +2.5% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | — | Buy | — | Reiterated | 11.06.26on TipRanks 20:15 | −0.7%next day −1.2% · 5 days +9.4% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | $31.00 | Buy | +26.9% | Reiterated | 23.10.25on TipRanks 04:50 | −2.8%next day +5.8% · 5 days +21.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Nurix Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $34.50 at a price of $23.71 (+45.5%); now: $34.18 at $24.42 (+40.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 19 | 11 | 9 | 2 | 3 |
| Buy | 1 | 3 | 10 | 11 | 9 | 4 |
| Hold | 0 | 1 | 2 | 2 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.02.27 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.41 (from $-0.81 to $0.05). Last quarter: $4.73.
Sales
Next quarter’s sales estimate — $38M (from $5M to $97M). Last quarter: $673M.
Best top-analyst consensus in the sector · Healthcare
About Nurix Therapeutics
- CEO: Arthur T. Sands
- Employees: 317
- 1600 Sierra Point Parkway, Brisbane, CA, 94005, US
- www.nurixtx.com
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Data from the stock’s TipRanks forecast page, read 41 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗